Goldman Sachs Starts Beta Bionics, Inc. (BBNX) at Neutral

Goldman Sachs analyst David Roman initiates coverage on Beta Bionics, Inc. (NASDAQ: BBNX) with a Neutral rating and a price target of $16.00.

The analyst comments: "We initiate coverage on shares of Beta Bionics (BBNX) with a Neutral rating and 12-month price target of $16. Our thesis on BBNX resides in our view that (1) the company’s technology (iLet) is well suited for a targeted segment of the Type 1 market; (2) with iLet in early stages of adoption, near-term growth should outpace Diabetes peers and SMID cap MedTech; and (3) consensus estimates seem to largely capture the opportunity over the next several years with valuation reflecting both that level of growth, as well as the need to raise further capital down the road to achieve cash flow breakeven, in our view."

For an analyst ratings summary and ratings history on Beta Bionics, Inc. click here. For more ratings news on Beta Bionics, Inc. click here.

Shares of Beta Bionics, Inc. closed at $15.36 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Mosaic sets pricing for tender offers on up to $1.4B in debt
• AI/ML Innovations plans $2M private placement on the CSE